Efractory Acute Myeloid Leukemia (AML)

It is a sign of chronic acute myeloidleukemia (AML) that has an isocitrate-dehydrogenase-2 (IDH2) mutation that was discovered by testing approved by the FDA

100 mg PO daily in combination with food or not up to the progression of the disease or unacceptably toxic

For patients who do not have any indication of progression or unacceptably toxic be treated for 6 months to allow for a clinical improvement

Dose modification

Hallucination syndrome

If you suspect discrimination syndrome If you suspect discrimination syndrome, give systemic corticosteroids. Begin monitoring of hemodynamics

Dosing with Intercadibib is recommended if pulmonary symptoms (eg intubation or ventilator support) and/or the kidneys are not improving after corticosteroid treatment after a period of> 48 hours

Reset Encenidib whenever symptoms or signs are improved (grade 2. (mild-moderate))

Non-infectious leukocytosis (WBC> 30,000 mcL)

In accordance with the standard institutional guidelines, start hydroxyurea in accordance with the standard guidelines of institutions.

Intercadibib dose when there is no improvement in leukocytosis following the onset of hydrosaurea

Resume enasidenib at 100 mg every day at the time that WBC is 30,000 mcL

Bilirubin elevated> 3x ULN

If you have not had constant AST/ALT or any other hepatic disorder during the ED2 weeks, decrease the dose of encenedib by 50 mg daily.

Resume doses of Encenedib at 100 mg/day after the basirubin-height solution (x2x ULN)

Other ysis grades 3 toxicity (eg cancer lysis syndrome)

Dosing Intersidenib until the toxicity in grade 2 is removed

If the toxicity is gone (1 level 1) Resume encenedib 50 mg/day; may increase to 100 mg/day

Close if grade 3 is more than to think

Examine baseline blood cells and chemistry for leukocytosis as well as the syndrome of tumors prior to beginning of ensenib. Monitor at least once a week for the initial three months of treatment.

Report this Page